Biotech Startup Due Diligence at Seed Stage: Complete Investor Guide
Companies developing novel therapeutics, diagnostics, genomics tools, and biological technologies for human health and disease treatment. This guide focuses specifically on due diligence considerations at the Seed stage ($1M–$5M raise, $6M–$25M post-money).
Seed Stage at a Glance
The company has demonstrated early product-market fit and is raising to build the team and accelerate growth toward Series A metrics.
Key Metrics for Biotech Startups at Seed
These are the 4 metrics that institutional investors evaluate for Biotech startups. DDR automatically extracts and benchmarks these from pitch deck data and OSINT sources.
Red Flags in Biotech Pitch Decks
DDR detects these 3 sector-specific red flags automatically when screening a Biotech startup pitch deck. Each flag is severity-weighted based on impact to investment thesis.
Due Diligence Focus Areas: Biotech
These are the priority investigation areas for Biotech startups that experienced investors always verify before committing capital.
- Scientific advisory board composition and engagement level
- Patent landscape: freedom-to-operate analysis and competitor IP
- Clinical trial design review with scientific expert
- Regulatory strategy: pre-IND meeting notes with FDA if available
- CMC (Chemistry, Manufacturing, and Controls) — manufacturing scalability
Key Questions to Ask the Founder
These founder interview questions surface the most common gaps and risks in Biotech startup pitches.
- What are the 3 biggest scientific risks in your program and what data would de-risk each one?
- What does success look like in Phase 2 — what endpoint are you powering for?
- Walk me through your IP strategy: what is the core patent and when does it expire?
- What is your clinical development cost and runway to the next major milestone?
Comparable Companies & Exits: Biotech
Regulatory & Compliance Risks
- FDA IND/NDA/BLA pathway: multiple review cycles, advisory committee meetings
- Clinical trial regulations: GCP compliance, IRB approval, informed consent
- Drug pricing scrutiny: IRA Medicare price negotiation for high-cost drugs
- EU EMA: separate approval pathway for European markets
OSINT Signals to Check
DDR automatically checks these 4 signals from public sources when analyzing a Biotech startup:
- ClinicalTrials.gov: registered study status and enrollment progress
- PubMed: peer-reviewed publications from founding team
- USPTO patent database: core composition-of-matter patents
- FDA warning letters database: any prior FDA actions
Biotech Due Diligence — All Guides
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →